Malawi

previous Print
ddHIV/AIDS Statistics for Malawi

Total population in thousands (2007): 13,925*
Number of people living with HIV (2007): 930,000*
Adults aged 15 to 49 prevalence rate (2007): 11.9*
Adults aged 15 and up living with HIV (2007): 840,000*
Women aged 15 and up living with HIV (2007): 490,000*
Children aged 0 to 14 living with HIV (2007): 91,000*
Deaths due to AIDS (2007): 68,000*
Orphans due to AIDS aged 0 to 17 (2007): 560,000*
Estimated antiretroviral therapy coverage (Dec 2007): 35%†
Population aged > or = to 15 years who received an HIV test (2007): 660,000†
Number of tests per 1000 population aged ≥ to 15 (2007): 89†
Estimated number of pregnant women living with HIV (2007): 73,000†


Ongoing biomedical HIV prevention research trials in Malawi
Microbicides PrEP PrEP & Microbicides Partner Treatment

Microbicides

Trial: Safety and acceptability of dapivirine gel, conducted using daily monitored adherence in healthy HIV-negative women [IPM 014A]
Phase: I/II
Product Being Tested: Dapivirine gel
Sponsor, funder, developer, collaborator: International Partnership for Microbicides, Johns Hopkins Project, College of Medicine
Total participants: 320
Countries: Kenya, Malawi, Rwanda, South Africa
Trial sites in Malawi:Blantyre
Results expected: n/a
For more information: http://clinicaltrials.gov/ct2/show/NCT00917904?term=IPM014B&rank=1
Back to Top ↑

Pre-Exposure Prophylaxis


Trial: Study to assess the role of Truvada® in preventing HIV acquisition in women [FEM-PrEP]
Phase: III
Product Being Tested: Daily oral TDF/FTC (Truvada®)
Sponsor, funder, developer, collaborator: FHI, United States Agency for International Development, Bill and Melinda Gates Foundation, Research, Training and Care Center - Kamuzu Central Hospital
Total participants: 3,900
Countries: Kenya, Malawi, South Africa, Tanzania, Zambia
Trial sites in Malawi: Lilongwe, Central Region; Blantyre, Southern Region
Results expected: 2013
For more information: http://clinicaltrials.gov/ct2/show/NCT00625404?term=FEM-PrEP&rank=1
Back to Top ↑

PrEP & Microbicides

Trial: Vaginal and Oral Interventions to Control the Epidemic [VOICE (MTN 003)]
Phase: IIb
Product Being Tested: Daily oral TDF; daily oral TDF/FTC; daily topical tenofovir gel
Sponsor, funder, developer, collaborator:Microbicide Trials Network, US National Institutes of Health
Total participants: 5,000
Countries: Malawi, South Africa, Uganda, Zimbabwe
Trial sites in Malawi:
Results expected:2013
For more information: http://www.mtnstopshiv.org/news/studies/mtn003
Back to Top ↑

Partner Treatment


Trial: Evaluation of the effectiveness of two antiretroviral treatment strategies to prevent HIV transmission in HIV-serodiscordant couples [HPTN 052]
Phase: III
Product Being Tested: Highly active antiretroviral therapy for HIV prevention
Sponsor, funder, developer, collaborator:HIV Prevention Trials Network, Malawi College of Medicine-Johns Hopkins University, University of North Carolina Lilongwe
Total participants: 1,750 couples
Countries: Botswana, Brazil, India, Kenya, Malawi, South Africa, Thailand, US, Zimbabwe
Trial sites in Malawi: Blantyre, Lilongwe
Results expected:
For more information: http://www.hptn.org/research_studies/hptn052.asp
Back to Top ↑
*WHO, UNAIDS, and UNICEF. Epidemiological Fact Sheet on HIV and AIDS: Core data on epidemiological and response Malawi 2008 Update. 2008. http://www.who.int/globalatlas/predefinedReports/EFS2008/full/EFS2008_MW.pdf
† WHO, UNAIDS, and UNICEF. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: Progress Report. 2008. http://www.who.int/hiv/pub/towards_universal_access_report_2008.pdf